Exact Sciences to participate in events, conferences during March

Mar 01, 2016, 16:30 ET from EXACT SCIENCES CORP

MADISON, Wis., March 1, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in two investor conferences and other events during March.

Kevin Conroy, the company's chairman and chief executive, will join Fight Colorectal Cancer leaders and other colon cancer advocates to ring the Nasdaq Closing Bell on Wednesday, March 2, at 4 p.m. ET.  The event will draw awareness to March Colon Cancer Awareness Month.

Mr. Conroy will make Exact Sciences' presentation at the 36th Annual Cowen and Company Health Care Conference in Boston at 8 a.m. ET on Tuesday, March 8.

On Sunday, March 13, at 5 p.m. CT, Mr. Conroy will join a panel discussion at SXSW 2016 titled "New Cancer Tech: Is Easy Detection a Reality?"  The group will review the impact of detecting cancer at its earliest, most treatable stages.

Mr. Conroy also will make the company's presentation at Roth Capital Partners' 28th Annual Roth Conference in Dana Point, Calif., at 3 p.m. PT on Monday, March 14.

A live webcast of the two investor presentations and Q&A sessions will be available through the company's website at www.exactsciences.com.  Archived webcasts will be available following the conclusion of the presentation.

About Exact Sciences Corp.
Exact Sciences Corp. is a molecular diagnostics company focused on gastrointestinal cancers. The company's noninvasive colorectal cancer screening test, Cologuard, is the first and only FDA-approved stool-based DNA test. Stool-based DNA technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer.  For more information, please visit the company's website at www.exactsciences.com.

Certain statements made in this presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "estimate," "anticipate" or other comparable terms. All statements other than statements of historical facts included in this presentation regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results, anticipated results of our sales and marketing efforts, expectations concerning payor reimbursement and the anticipated results of our product development efforts. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to successfully and profitably market our products and services; the acceptance of our products and services by patients and health care providers; the willingness of health insurance companies and other payors to reimburse us for our performance of the Cologuard test; the amount and nature of competition from other cancer screening products and services; the effects of any healthcare reforms or changes in healthcare pricing, coverage and reimbursement; recommendations, guidelines and/or quality-of-care metrics issued by various organizations such as the U.S. Preventive Services Task Force, the American Cancer Society and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services; our success establishing and maintaining collaborative and licensing arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contact:
J.P. Fielder
Senior Director, Corporate Communications, Exact Sciences Corp.
608-210-5220
jpfielder@exactsciences.com

Logo - http://photos.prnewswire.com/prnh/20160108/320353

 

SOURCE EXACT SCIENCES CORP



RELATED LINKS

http://www.exactsciences.com